Dr. Robert Rottapel
Dr. Robert Rottapel
Dr. Robert Rottapel
Senior Investigator & Co-Leader,
Ovarian Cancer TRI

Donna De Francesco

Senior Investigator & Co-Leader,
Ovarian Cancer TRI

The Rottapel laboratory uses functional genetic screens (both shRNA and CRISPR/Cas9) to identify novel vulnerabilities in ovarian cancer as a strategy to develop new therapeutic targets. They focus on understanding signal transduction pathways that operate in normal and cancer cells and the regulatory processes that control protein function. The lab is particularly interested in targeting adaptive stress pathways that support the transformed cancer state as a strategy to find new anti-cancer therapies.

Other areas of research pursued in the laboratory focus on signal transduction pathways in the immune system and the study of monogenic human diseases that control inflammation, bone homeostasis and metabolism.

Experience & Education
  • Program Director, Innovation in Target Validation, OICR
  • Amgen Chair for Cancer Research, University Health Network
Current Affiliations
  • Senior Investigator, OICR
  • Co-Leader, Ovarian Cancer Translational Research Initiative
  • Senior Scientist and Amgen Chair for Cancer Research, Princess Margaret Cancer Centre
  • Professor, Departments of Medicine, Immunology and Medical Biophysics, University of Toronto
  • Rheumatologist, Department of Medicine, St. Michael’s Hospital, Toronto
Select Publications

See Dr. Rottapel’s recent publications on PubMed or on Google Scholar.

Research Areas
Disease Areas
Ovarian Pancreatic
Opportunities to Collaborate
  • Target validation in ovarian cancer
  • Development of novel small molecule or antibody based therapeutics
  • Mechanism of transformation underlying ovarian cancer
  • CRISPR/CAS9 functional genetic screens
  • Drug sensitizing screens

Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.